Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,492 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thyroid autoantibodies at baseline predict longer survival in non-small cell lung cancer patients treated with anti-programmed cell death-1 blockade: a prospective study.
Okuji T, Iwama S, Kobayashi T, Yasuda Y, Ito M, Yamagami A, Ando M, Hase T, Shibata H, Hatta T, Zhou X, Onoue T, Kawaguchi Y, Miyata T, Sugiyama M, Hagiwara D, Suga H, Banno R, Ando Y, Hashimoto N, Arima H. Okuji T, et al. Among authors: ando y, ando m. Nagoya J Med Sci. 2024 Aug;86(3):452-463. doi: 10.18999/nagjms.86.3.452. Nagoya J Med Sci. 2024. PMID: 39355355 Free PMC article.
Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L.
Kogure Y, Ando M, Saka H, Chiba Y, Yamamoto N, Asami K, Hirashima T, Seto T, Nagase S, Otsuka K, Yanagihara K, Takeda K, Okamoto I, Aoki T, Takayama K, Yamasaki M, Kudoh S, Katakami N, Miyazaki M, Nakagawa K. Kogure Y, et al. Among authors: ando m. J Thorac Oncol. 2013 Jun;8(6):753-8. doi: 10.1097/JTO.0b013e31828b51f5. J Thorac Oncol. 2013. PMID: 23575412 Free article.
Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System.
Morise M, Taniguchi H, Saka H, Shindoh J, Suzuki R, Kojima E, Hase T, Ando M, Kondo M, Saito H, Hasegawa Y. Morise M, et al. Among authors: ando m. Mol Clin Oncol. 2014 Nov;2(6):991-996. doi: 10.3892/mco.2014.354. Epub 2014 Jul 22. Mol Clin Oncol. 2014. PMID: 25279187 Free PMC article.
Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.
Gemma A, Kudoh S, Ando M, Ohe Y, Nakagawa K, Johkoh T, Yamazaki N, Arakawa H, Inoue Y, Ebina M, Kusumoto M, Kuwano K, Sakai F, Taniguchi H, Fukuda Y, Seki A, Ishii T, Fukuoka M. Gemma A, et al. Among authors: ando m. Cancer Sci. 2014 Dec;105(12):1584-90. doi: 10.1111/cas.12550. Cancer Sci. 2014. PMID: 25287435 Free PMC article. Clinical Trial.
3,492 results